EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Network Pharmacology-Serum Metabolomics Integration Identifies Key Targets, Biomarkers and Mechanism of Sendeng-4 in Rheumatoid Arthritis Therapy

Fengye Zhou, Jun Li, Yiyang Zhou, Xueying Zhang, Jun Luo, Xinkui Li, Wenlong Sun, Qian Zhang iD, Mengyao Li iD

International Journal of General Medicine · 2026-04 · Volume 19 · 1-24

DOI: 10.2147/ijgm.s597129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of General Medicine, 2026-04. Verfasst von Fengye Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Rheumatoid arthritis (RA) is characterized by chronic inflammatory synovitis and immunometabolic dysregulation, necessitating safer multi-target therapies. Sendeng-4 (SD-4) is a traditional Mongolian medicinal formula composed of four botanical ingredients (Xanthoceras sorbifolia Bunge, Gardenia jasminoides Ellis, Chebulae Fructus, and Toosendan Fructus) traditionally used for RA. However, its circulating material basis and mechanisms remain unclear. This study aimed to elucidate the pharmacodynamic constituents and potential mechanisms of SD-4 in RA.

Methods

An integrative approach combining serum pharmacochemistry, network pharmacology, molecular docking, in vivo pharmacodynamics, and non-targeted serum metabolomics was employed. Absorbable constituents of SD-4 were identified by HPLC-Q-Exactive-Orbitrap-MS. Key targets and pathways were explored using network analysis, and therapeutic efficacy and metabolomic biomarkers were evaluated in a collagen-induced arthritis mouse model.

Results

Twenty absorbable constituents were detected, with SRC, PIK3CA, and PIK3R1 emerging as key targets involved in PI3K-AKT and HIF-1 signaling. SD-4 treatment significantly reduced arthritis scores (by up to 45% in high-dose mice), paw thickness, and serum pro-inflammatory cytokines (TNF-α, IL-6, IL-1β decreased by 30-55%, all P < 0.05). Serum metabolomics identified 46 disease-associated metabolites reversed by SD-4, particularly involving tryptophan metabolism and glycolysis/gluconeogenesis. Correlation analyses suggest these metabolic changes are associated with modulation of inflammatory pathways.

Conclusion

SD-4 alleviates arthritis in mice, likely through modulation of the PI3K/SRC network and partial rebalancing of glycolysis-tryptophan metabolic crosstalk, restoring immunometabolic homeostasis. These findings support the potential clinical application of SD-4 for RA and provide a mechanistic framework for its multi-target actions.

Schlagwörter

Stichwörter der Autor:innen

SenDeng-4absorbed componentsnetwork pharmacologyrheumatoid arthritis therapyserum metabolomics

Autor:innen und Institutionen

  • Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People's Republic of China.
  • College of Pharmacy, Inner Mongolia Medical University, Hohhot, Inner Mongolia, People's Republic of China.
  • The First Clinical School of Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia, People's Republic of China.
  • School of Computer Science and Information Technology, Inner Mongolia Medical University, Hohhot, Inner Mongolia, People's Republic of China.
  • School of Life Sciences and Medicine, Shandong University of Technology, Zibo, Shandong, People's Republic of China.
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

ORCID-Profile: Qian Zhang, Mengyao Li

Zitieren

APA

Zhou, F., Li, J., Zhou, Y., Zhang, X., Luo, J., Li, X., Sun, W., Zhang, Q., & Li, M. (2026). Network Pharmacology-Serum Metabolomics Integration Identifies Key Targets, Biomarkers and Mechanism of Sendeng-4 in Rheumatoid Arthritis Therapy. International Journal of General Medicine, Volume 19, 1-24. https://doi.org/10.2147/ijgm.s597129

Vancouver

Zhou F, Li J, Zhou Y, Zhang X, Luo J, Li X, et al. Network Pharmacology-Serum Metabolomics Integration Identifies Key Targets, Biomarkers and Mechanism of Sendeng-4 in Rheumatoid Arthritis Therapy. International Journal of General Medicine. 2026;Volume 19:1-24. doi:10.2147/ijgm.s597129

BibTeX
@article{Zhou2026,
  author = {Zhou, Fengye and Li, Jun and Zhou, Yiyang and Zhang, Xueying and Luo, Jun and Li, Xinkui and Sun, Wenlong and Zhang, Qian and Li, Mengyao},
  title = {Network Pharmacology-Serum Metabolomics Integration Identifies Key Targets, Biomarkers and Mechanism of Sendeng-4 in Rheumatoid Arthritis Therapy},
  journal = {International Journal of General Medicine},
  year = {2026},
  volume = {Volume 19},
  pages = {1--24},
  doi = {10.2147/ijgm.s597129}
}
Kostenlos starten →